Trial Profile
Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Digoxin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 23 Jun 2017 Status changed from recruiting to discontinued as PI Leaving Site.
- 23 Jul 2013 New trial record